Tisotumab Vedotin (Tivdak) for Cervical Cancer
The Medical Letter on Drugs and Therapeutics · 24.06.2024 · 66 (1705) · e109-e110
DOI: 10.58347/tml.2024.1705g ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 24.06.2024. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Tisotumab vedotin-tftv (Tivdak – Seagen/Genmab), a tissue factor-directed antibody and microtubule inhibitor conjugate, has received full approval from the FDA for treatment of recurrent or metastatic cervical cancer that progressed on or after chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2024). Tisotumab Vedotin (Tivdak) for Cervical Cancer. The Medical Letter on Drugs and Therapeutics, 66(1705), e109-e110. https://doi.org/10.58347/tml.2024.1705g
Vancouver
Tisotumab Vedotin (Tivdak) for Cervical Cancer. The Medical Letter on Drugs and Therapeutics. 2024;66(1705):e109-e110. doi:10.58347/tml.2024.1705g
BibTeX
@article{euvimed2024,
title = {Tisotumab Vedotin (Tivdak) for Cervical Cancer},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2024},
volume = {66},
number = {1705},
pages = {e109--e110},
doi = {10.58347/tml.2024.1705g}
}
EUVIMED